Operating Lease, Payments of Inozyme Pharma, Inc. from 31 Dec 2020 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Inozyme Pharma, Inc. quarterly and annual Operating Lease, Payments in USD history and change rate from 31 Dec 2020 to 31 Mar 2025.
  • Inozyme Pharma, Inc. Operating Lease, Payments for the quarter ending 31 Mar 2025 was $300,000.
  • Inozyme Pharma, Inc. annual Operating Lease, Payments for 2024 was $1,000,000, a 43% increase from 2023.
  • Inozyme Pharma, Inc. annual Operating Lease, Payments for 2023 was $700,000, a 22% decline from 2022.
  • Inozyme Pharma, Inc. annual Operating Lease, Payments for 2022 was $900,000, unchanged from 2021.
Source SEC data
View on sec.gov
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Change (%)

Inozyme Pharma, Inc. Quarterly Operating Lease, Payments (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $300,000 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q1 2021 $200,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2021 2021 Q1

Inozyme Pharma, Inc. Annual Operating Lease, Payments (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,000,000 +$300,000 +43% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $700,000 -$200,000 -22% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $900,000 $0 0% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2023 2022 FY
2021 $900,000 +$300,000 +50% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $600,000 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.